

World Journal of *Clinical Cases*

World J Clin Cases 2020 January 6; 8(1): 1-244



REVIEW

- 1 Role of oxysterol-binding protein-related proteins in malignant human tumours
Liu H, Huang S

ORIGINAL ARTICLE**Case Control Study**

- 11 Oncogenic role of Tc17 cells in cervical cancer development
Zhang ZS, Gu Y, Liu BG, Tang H, Hua Y, Wang J

Retrospective Study

- 20 Acute distal common bile duct angle is risk factor for post-endoscopic retrograde cholangiopancreatography pancreatitis in beginner endoscopist
Han SY, Kim DU, Lee MW, Park YJ, Baek DH, Kim GH, Song GA
- 29 Three-dimensional computed tomography mapping of posterior malleolar fractures
Su QH, Liu J, Zhang Y, Tan J, Yan MJ, Zhu K, Zhang J, Li C
- 38 Application of a modified surgical position in anterior approach for total cervical artificial disc replacement
Hou WX, Zhang HX, Wang X, Yang HL, Luan XR
- 46 Potential role of the compound Eucommia bone tonic granules in patients with osteoarthritis and osteonecrosis: A retrospective study
Hu CX, Hu KY, Wang JF
- 54 Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: A study of 1358 patients
Cui PF, Cong XF, Gao F, Yin JX, Niu ZR, Zhao SC, Liu ZL
- 68 Application of multiple Roux-en-Y hepaticojejunostomy reconstruction by formation of bile hilar duct lake in the operation of hilar cholangiocarcinoma
Yang XJ, Dong XH, Chen SY, Wu B, He Y, Dong BL, Ma BQ, Gao P

Observational Study

- 76 Relationship between β -amyloid protein 1-42, thyroid hormone levels and the risk of cognitive impairment after ischemic stroke
Mao L, Chen XH, Zhuang JH, Li P, Xu YX, Zhao YC, Ma YJ, He B, Yin Y

Prospective Study

- 88 Can the wet suction technique change the efficacy of endoscopic ultrasound-guided fine-needle aspiration for diagnosing autoimmune pancreatitis type 1? A prospective single-arm study
Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Watanabe K, Nakamura J, Kikuchi H, Takasumi M, Hashimoto M, Kato T, Hikichi T, Notohara K, Ohira H

CASE REPORT

- 97 Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report
Cimpeanu E, Ahmed J, Zafar W, DeMarinis A, Bardarov SS, Salman S, Bloomfield D
- 103 Sclerosing angiomatoid nodular transformation of the spleen, a rare cause for splenectomy: Two case reports
Chikhladze S, Lederer AK, Fichtner-Feigl S, Wittel UA, Werner M, Aumann K
- 110 Postpartum pubic symphysis diastasis-conservative and surgical treatment methods, incidence of complications: Two case reports and a review of the literature
Norvilaite K, Kezeviciute M, Ramasauskaite D, Arlauskiene A, Bartkeviciene D, Uvarovas V
- 120 Use of omental patch and endoscopic closure technique as an alternative to surgery after endoscopic full thickness resection of gastric intestinal stromal tumors: A series of cases
Sachdev AH, Iqbal S, Ribeiro IB, de Moura DTH
- 126 Primary maxillary chondrosarcoma: A case report
Cuevas-González JC, Reyes-Escalera JO, González JL, Sánchez-Romero C, Espinosa-Cristóbal LF, Reyes-López SY, Tovar Carrillo KL, Donohue Cornejo A
- 133 Hyalinizing clear cell carcinoma-a rare entity in the oral cavity: A case report
Donohue-Cornejo A, Paes de Almeida O, Sánchez-Romero C, Espinosa-Cristóbal LF, Reyes-López SY, Cuevas-González JC
- 140 Jejunal cavernous lymphangioma manifested as gastrointestinal bleeding with hypogammaglobulinemia in adult: A case report and literature review
Tan B, Zhang SY, Wang YN, Li Y, Shi XH, Qian JM
- 149 Large pelvic mass arising from the cervical stump: A case report
Zhang K, Jiang JH, Hu JL, Liu YL, Zhang XH, Wang YM, Xue FX
- 157 Mechanical intestinal obstruction due to isolated diffuse venous malformations in the gastrointestinal tract: A case report and review of literature
Li HB, Lv JF, Lu N, Lv ZS
- 168 Two-level percutaneous endoscopic lumbar discectomy for highly migrated upper lumbar disc herniation: A case report
Wu XB, Li ZH, Yang YF, Gu X

- 175 Successful treatment of congenital palate perforation: A case report
Zhang JF, Zhang WB
- 179 Calcitonin-negative neuroendocrine tumor of the thyroid with metastasis to liver-rare presentation of an unusual tumor: A case report and review of literature
Cai HJ, Wang H, Cao N, Huang B, Kong FL, Lu LR, Huang YY, Wang W
- 188 Giant exophytic cystic adenomyosis with a levonorgestrel containing intrauterine device out of the uterine cavity after uterine myomectomy: A case report
Zhou Y, Chen ZY, Zhang XM
- 194 Unusual presentation of bladder neuroblastoma in a child: A case report
Cai JB, Wang JH, He M, Wang FL, Xiong JN, Mao JQ, Li MJ, Zhu K, Liang JW
- 200 Value of dynamic plasma cell-free DNA monitoring in septic shock syndrome: A case report
Liu JP, Zhang SC, Pan SY
- 208 Sarcomatoid intrahepatic cholangiocarcinoma mimicking liver abscess: A case report
Wang Y, Ming JL, Ren XY, Qiu L, Zhou LJ, Yang SD, Fang XM
- 217 Clinical characteristics on manifestation and gene mutation of a transient neonatal cyanosis: A case report
Yuan J, Zhu XP
- 222 Six families with balanced chromosome translocation associated with reproductive risks in Hainan Province: Case reports and review of the literature
Chen YC, Huang XN, Kong CY, Hu JD
- 234 Primary intestinal extranodal natural killer/T-cell lymphoma, nasal type: A case report
Dong BL, Dong XH, Zhao HQ, Gao P, Yang XJ

LETTER TO THE EDITOR

- 242 Cluster headache as a manifestation of a stroke-like episode in a carrier of the *MT-ND3* variant m.10158T>C
Finsterer J

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Maddalena Zippi, MD, PhD, Doctor, Unit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, Rome 00157, Italy

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases (WJCC, World J Clin Cases)* is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The *WJCC* is now indexed in PubMed, PubMed Central, Science Citation Index Expanded (also known as SciSearch®), and Journal Citation Reports/Science Edition. The 2019 Edition of Journal Citation Reports cites the 2018 impact factor for *WJCC* as 1.153 (5-year impact factor: N/A), ranking *WJCC* as 99 among 160 journals in Medicine, General and Internal (quartile in category Q3).

RESPONSIBLE EDITORS FOR THIS ISSUE

Responsible Electronic Editor: *Yan-Xia Xing*

Proofing Production Department Director: *Yun-Xiaojuan Wu*

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Semimonthly

EDITORS-IN-CHIEF

Dennis A Bloomfield, Bao-Gan Peng, Sandro Vento

EDITORIAL BOARD MEMBERS

<https://www.wjnet.com/2307-8960/editorialboard.htm>

EDITORIAL OFFICE

Jin-Lei Wang, Director

PUBLICATION DATE

January 6, 2020

COPYRIGHT

© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjnet.com/bpg/gerinfo/240>

PUBLICATION MISCONDUCT

<https://www.wjnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report

Emanuela Cimpeanu, Jibran Ahmed, Wahib Zafar, Adreana DeMarinis, Svetoslav S Bardarov, Shamim Salman, Dennis Bloomfield

ORCID number: Emanuela Cimpeanu (0000-0001-6334-2743); Jibran Ahmed (0000-0002-3412-7689); Wahib Zafar (0000-0001-5987-5475); Adreana DeMarinis (0000-0002-6060-7475); Svetoslav S Bardarov (0000-0001-6481-4976); Shamim Salman (0000-0001-7490-6743); Dennis Bloomfield (0000-0001-7702-2222).

Author contributions: Cimpeanu E cared for the patient, conceived and designed the case report and wrote most of the manuscript; Jibran A and Zafar W cared for the patient, conceived and designed the case report and wrote part of the manuscript; DeMarinis A cared for the patient and wrote part of the manuscript; Bardarov SS provided the pathology data as well as the histology images and their description and also revised the manuscript; Salman S cared for the patient, conceived and designed the case report and made critical revisions to the manuscript; Bloomfield D conceived and designed the case report and made multiple critical revisions to the manuscript.

Informed consent statement:

Consent to publish was obtained from the patient in the study.

Conflict-of-interest statement:

The authors declare that they have no competing interests.

CARE Checklist (2016) statement:

The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Emanuela Cimpeanu, Adreana DeMarinis, Dennis Bloomfield, Department of Internal Medicine, Richmond University Medical Center, Staten Island, NY 10310, United States

Jibran Ahmed, Wahib Zafar, Department of Hematology and Medical Oncology, Westchester Medical Center, Valhalla, NY 10595, United States

Svetoslav S Bardarov, Department of Pathology, Richmond University Medical Center, Staten Island, NY 10310, United States

Shamim Salman, Department of Hematology and Medical Oncology, Richmond University Medical Center, Staten Island, NY 10310, United States

Dennis Bloomfield, Department of Clinical Research, Richmond University Medical Center, Staten Island, NY 10310, United States

Corresponding author: Emanuela Cimpeanu, MD, Doctor, Resident Physician, Department of Internal Medicine, Richmond University Medical Center, 355 Bard Ave, Staten Island, NY 10310, United States. emma_ver@yahoo.com

Abstract

BACKGROUND

Few studies have addressed the efficacy of pembrolizumab in pulmonary sarcomatoid carcinoma (PSC), a rare, previously rapidly fatal subtype of non-small-cell lung cancer.

CASE SUMMARY

We report the case of a 69-year-old man presented with respiratory distress caused by a large left upper lung lobe mass diagnosed as PSC with programmed death-ligand 1 expressed on more than 50 percent of tumor cells. The patient was started on pembrolizumab and, after 5 cycles, there was a more than 80 percent decrease in the size of the tumor mass. Further decrease was seen at the end of 10 cycles. The patient has been tolerating pembrolizumab well, with no limiting side-effects. Fourteen months after first coming into the hospital, he remains asymptomatic.

CONCLUSION

Pembrolizumab appears as a viable emerging treatment for PSC.

Key words: Pembrolizumab; Pulmonary sarcomatoid carcinoma; Programmed death-ligand 1; Platinum-based chemotherapy; Non-small-cell lung cancer; Overall survival;

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Received: September 11, 2019

Peer-review started: September 11, 2019

First decision: October 24, 2019

Revised: November 5, 2019

Accepted: November 14, 2019

Article in press: November 14, 2019

Published online: January 6, 2020

P-Reviewer: Vanoli A

S-Editor: Dou Y

L-Editor: A

E-Editor: Wu YXJ



Case report

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Pulmonary sarcomatoid carcinoma (PSC) is classified as a rare, aggressive subtype of non-small-cell lung cancer. In recent years, pembrolizumab, a humanized monoclonal IgG-kappa isotype antibody against the programmed death-1 receptor, has become the first-line treatment for NSCLE with programmed death-ligand-1 (PD-L1) expression on at least 50% of tumor cells. We report the case of an elderly man diagnosed with invasive PSC with PD-L1 greater than 50%. The patient experienced a highly positive response to pembrolizumab. The recommendation to treat PSC with pembrolizumab is supported by the small number of published papers available in the English literature.

Citation: Cimpeanu E, Ahmed J, Zafar W, DeMarinis A, Bardarov SS, Salman S, Bloomfield D. Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report. *World J Clin Cases* 2020; 8(1): 97-102

URL: <https://www.wjnet.com/2307-8960/full/v8/i1/97.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v8.i1.97>

INTRODUCTION

Pulmonary sarcomatoid carcinoma (PSC) represents a high-grade histologic subtype of non-small-cell lung cancer (NSCLC), accounting for only about 1% of NSCLC and 0.4% of all lung cancers in the United States^[1,2]. Most are diagnosed at advanced stages and have an aggressive clinical course and lower overall survival than other histologic subtypes, even on the rare occasions when discovered incipiently^[2]. Management of metastatic disease has been challenging, owing to high rates of resistance to conventional platinum-based chemotherapy, which, up to recently, was the preferred treatment option for all metastatic types^[2-4]. While response to pembrolizumab in the more common subtypes of NSCLC has been reported by several studies, very few have addressed the efficacy of pembrolizumab in PSC. We report a case of excellent response to pembrolizumab in a patient with PSC characterized by programmed death-ligand 1 (PD-L1) expression greater than 50%.

CASE PRESENTATION

Chief Complaints

A 69-year-old man presented with one week's duration of respiratory distress and diffuse, intermittent and non-radiating left upper chest pain.

History of present illness

The patient began experiencing occasional dry cough two months prior to presentation but denied having any other symptoms.

History of past illness

There was a past medical history of 60 pack-year smoking, hypertension, diabetes mellitus type II, hypothyroidism, Parkinson's disease and depression.

Physical examination

The patient had labored and irregular breathing but did not use the accessory muscles of respiration. There was tenderness to palpation of the left chest wall and dullness to percussion in the left upper lung field, with decreased breath sounds, rhonchi and slight wheezing. There was mild diffuse abdominal tenderness, without guarding.

Laboratory examinations

Laboratory workup revealed white blood cell count 22.9 K/uL, hemoglobin 10.8 g/dL, hematocrit 37.0%, platelet count 943 K/uL, erythrocyte sedimentation rate 130, serum potassium 5.4 mmol/L and serum calcium 11.6 mg/dL.

Imaging examinations

Chest computed tomography (CT) demonstrated a solid, heterogeneous, partially necrotic mass occupying the left upper lobe, encasing the left subclavian artery and extending into the left mediastinum (Figure 1A, 1B). Abdominal and pelvic CT showed hepatomegaly. There was extensive destruction of the left first rib, with less severe involvement of the left second rib, but no evidence of mediastinal, hilar or axillary adenopathy.

FINAL DIAGNOSIS

Biopsy of the mass revealed a poorly differentiated neoplasm composed predominantly of spindle cells, with rare epithelioid cells and large bizarre nuclei (Figure 2A). The immunohistochemical analysis of the lesion demonstrated that the neoplastic cells were positive for cytokeratin-7 (CK-7) (Figure 2B) but negative for thyroid transcription factor-1, p40, CK20, prostate-specific antigen, and MelanA. In addition, immunohistochemical stains for mesothelial origin, specifically Calretinin, CK5/6 and podoplanin (D2-40) were negative. The negative p40 and CK5/6 also ruled out sarcomatoid squamous cell carcinoma. The neoplastic cells tested positive for PD-L1, with a tumor proportion score greater than 50% (Figure 2C). No mutations in epidermal growth factor receptor (EGFR) exons 18, 19 or 21 and KRAS codons 12, 13 or 61 were present. An exon 20 insertion was identified but the mass was EGFR T790M-negative. Anaplastic lymphoma kinase (ALK) and receptor tyrosine kinase (ROS) translocations were not performed since EGFR and KRAS mutations are mutually exclusive with these translocations. The tumor was classified as stage IIIa (T4N1M0) PSC.

TREATMENT

IV fluids, Pamidronate and antibiotics were administered, and the patient's condition stabilized. Given multiple medical comorbidities, surgical debulking was not feasible. As the tumor was causing airway compromise, palliative radiation therapy was initiated. The patient was also started on pembrolizumab (200 mg) every 21 d.

OUTCOME AND FOLLOW-UP

A repeat CT scan of the chest after 5 cycles of pembrolizumab showed a decrease of more than 80 percent in the size of the tumor mass (Figure 1C, 1D).

Positron emission tomography-CT (PET-CT) scan at the end of 10 cycles showed an even further decrease (Figure 3). The patient has been tolerating pembrolizumab well, with no limiting side-effects and a plan was made to continue the same treatment. At present, 14 mo after first coming into the hospital, he remains asymptomatic.

DISCUSSION

When diagnosed, PSCs are frequently bulky, peripherally located and already metastatic, with poor prognosis^[1]. For a patient like ours, with stage III tumor, overall survival is estimated at 5.8 mo, whereas for stages I-II it is 16.9 mo and for stage IV 5.4 mo^[5]. The typical patient has a history of heavy smoking^[1]. PSCs are more widespread in Caucasians (89%) and males (59%)^[5]. The mean age at diagnosis is 70 years^[5]. Our patient fits these exact demographics - male, Caucasian, heavy smoker, in his late 60s and with an advanced malignancy. Improved survival in PSC is seen when tumors are localized, amenable to complete surgical resection, 4 cm or less in size, and when patients are not underweight or anemic^[6]. Our patient was not underweight but lacked other positive prognostic factors. He was, in fact, anemic and had a large, locally-invasive tumor, which put him at increased risk for a less favorable outcome.

Platinum-based chemotherapy has proven disappointing in PSC, with most patients (69%) experiencing disease progression and overall survival being only slightly increased compared to the non-platinum group (7.0 vs 5.3 mo)^[3]. Compared to patients not receiving any treatment, platinum-based chemotherapy resulted in a median overall survival of only 51 d longer^[7]. Decreased survival in PSC has been largely attributed to its aggressive nature as well as chemoresistance^[1]. The marginal performance of available treatment options warranted a need for new therapeutic




Figure 1 Chest computed tomography. A, B: Prior to initiation of pembrolizumab, with yellow arrows pointing to a left upper lobe primary measuring 14.1 cm × 10.6 cm × 14.9 cm. C, D: After 5 cycles of pembrolizumab, with yellow arrows pointing to a markedly decreased left upper lobe mass measuring 8.0 cm × 7.7 cm × 6.8 cm.

strategies.

The introduction of pembrolizumab, a monoclonal IgG4 kappa isotype antibody against the Programmed Death 1 pathway, for NSCLC lacking targetable EGFR or ALK mutations has resulted in improved overall survival and progression-free survival for NSCLC with PD-L1 on at least 50% of tumor cells^[4,8]. Pembrolizumab has become the first-line treatment for such tumor^[4]. KEYNOTE studies (021, 024 and 189) all showed improved treatment response when pembrolizumab was added to platinum-based chemotherapy^[4,9,10]. In addition, patients on pembrolizumab benefited from increased overall survival, greater response rate, longer duration of response and fewer adverse effects secondary to treatment^[10]. However, the application of pembrolizumab for PSC has been minimally reported. On a Pubmed search, there are three other individual cases published supporting our contention that pembrolizumab is effective in this previously rapidly fatal tumor^[11-13]. There are six other cases in which a form of immunotherapy has been used, however, the outcome is unclear^[14,15].

For PSCs with mutated EGFR, EGFR tyrosine kinase inhibitors (TKIs) can be a more suitable treatment option^[16]. Third generation EGFR-TKIs have proven efficacious in tumors with EGFR mutations in exons 19 and 21 as well as exon 20 T790M mutations^[17]. Osimertinib, a third-generation EGFR-TKI, is particularly indicated for EGFR-mutant NSCLC with an acquired T790M resistance mutation, progressing during or following treatment with EGFR-TKIs^[17]. Our patient lacked EGFR targetable mutations. The tumor was in fact positive for an EGFR exon 20 insertion, which is seen in about 9% of all EGFR-mutated tumors and has been linked to de-novo resistance to EGFR-TKI^[18]. For these reasons, EGFR-TKIs were not an appropriate choice.

CONCLUSION

The efficacy of pembrolizumab in the treatment of PSC has not been adequately studied. In our patient, it was proven a highly beneficial form of treatment. He continued to be asymptomatic, more than 14 mo after presentation. To date, this is one of the most sustained responses of PSC to an immune checkpoint inhibitor reported in the English literature. For PSC patients with PD-L1 expression on 50% or more of tumor cells, pembrolizumab is a viable option.




Figure 2 Histological lung section. A: Hematoxylin and eosin staining showing sarcomatoid carcinoma, with visible spindle cells and rare epithelioid cells (magnification, 100 ×); B: Immunohistochemical staining showing sarcomatoid carcinoma with neoplastic cells positive for CK7 (magnification, 200 ×); C: Hematoxylin and eosin staining showing sarcomatoid carcinoma, with cells positive for programmed *death-ligand-1* and tumor proportion score greater than 50% (magnification, 400×).




Figure 3 Chest positron emission tomography - computed tomography (lung window) after 9 cycles of pembrolizumab, with the yellow arrow pointing to a fluorodeoxyglucose-avid 5.5 cm × 4 cm mass in the left upper lobe, with central necrosis and a maximum standardized uptake value of 8.6, consistent with malignancy. Inferiorly and in its continuation, there is a second lesion measuring 2.3 cm × 1.8 cm with a maximum standardized uptake value of 7.2, interpreted as a remnant from the initial tumor.

REFERENCES

- 1 **Antoine M**, Vieira T, Fallet V, Hamard C, Duruisseaux M, Cadranel J, Wislez M. [Pulmonary sarcomatoid carcinoma]. *Ann Pathol* 2016; **36**: 44-54 [PMID: [26778815](#) DOI: [10.1016/j.anpat.2015.11.007](#)]
- 2 **Yendamuri S**, Caty L, Pine M, Adem S, Bogner P, Miller A, Demmy TL, Groman A, Reid M. Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis. *Surgery* 2012; **152**: 397-402 [PMID: [22739072](#) DOI: [10.1016/j.surg.2012.05.007](#)]
- 3 **Vieira T**, Girard N, Ung M, Monnet I, Cazes A, Bonnette P, Duruisseaux M, Mazieres J, Antoine M, Cadranel J, Wislez M. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. *J Thorac Oncol* 2013; **8**: 1574-1577 [PMID: [24389441](#) DOI: [10.1097/01.JTO.0000437008.00554.90](#)]
- 4 **Gandhi L**, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. *N Engl J Med* 2018; **378**: 2078-2092 [PMID: [29658856](#) DOI: [10.1056/NEJMoa1801005](#)]
- 5 **Steuer CE**, Behera M, Liu Y, Fu C, Gillespie TW, Saba NF, Shin DM, Pillai RN, Pakkala S, Owonikoko TK, Khuri FR, Ramalingam SS. Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base. *Clin Lung Cancer* 2017; **18**: 286-292 [PMID: [28043773](#) DOI: [10.1016/j.clcc.2016.11.016](#)]
- 6 **Lin Y**, Yang H, Cai Q, Wang D, Rao H, Lin S, Long H, Fu J, Zhang L, Lin P, Xu G, Rong T, Xiong X, Ma G, Liang Y. Characteristics and Prognostic Analysis of 69 Patients With Pulmonary Sarcomatoid Carcinoma. *Am J Clin Oncol* 2016; **39**: 215-222 [PMID: [25068469](#) DOI: [10.1097/COC.0000000000001011](#)]
- 7 **Karim NA**, Schuster J, Eldessouki I, Gaber O, Namad T, Wang J, Xie C, Morris JC. Pulmonary sarcomatoid carcinoma: University of Cincinnati experience. *Oncotarget* 2018; **9**: 4102-4108 [PMID: [29423107](#) DOI: [10.18632/oncotarget.23468](#)]
- 8 **Le DT**, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Lubner BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhajee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B,

- Diaz LA. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med* 2015; **372**: 2509-2520 [PMID: 26028255 DOI: 10.1056/NEJMoa1500596]
- 9 **Langer CJ**, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. *Lancet Oncol* 2016; **17**: 1497-1508 [PMID: 27745820 DOI: 10.1016/S1470-2045(16)30498-3]
 - 10 **Reck M**, Rodriguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. *N Engl J Med* 2016; **375**: 1823-1833 [PMID: 27718847 DOI: 10.1056/NEJMoa1606774]
 - 11 **Matsumoto Y**, Miura T, Horiuchi H, Usui K. The Successful Treatment of Pulmonary Pleomorphic Carcinoma with Pembrolizumab: A Case Report. *Case Rep Oncol* 2017; **10**: 752-757 [PMID: 28878661 DOI: 10.1159/000479552]
 - 12 **Ikematsu Y**, Yoneshima Y, Ijichi K, Tanaka K, Harada T, Oda Y, Nakanishi Y, Okamoto I. Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1. *Lung Cancer* 2017; **112**: 230-231 [PMID: 28754417 DOI: 10.1016/j.lungcan.2017.07.020]
 - 13 **Tokuyasu H**, Ishikawa S, Sakai H, Ikeuchi T, Miura H. Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma. *Respir Med Case Rep* 2019; **28**: 100879 [PMID: 31249776 DOI: 10.1016/j.rmcr.2019.100879]
 - 14 **Kotłowska MP**, Rueda AG, Olmedo ME, Benito A, Roldán AS, Fernández Méndez MA, Gorospe L, Palacios J, Garrido López P. Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review. *Respir Med Case Rep* 2019; **26**: 310-314 [PMID: 30931249 DOI: 10.1016/j.rmcr.2019.02.017]
 - 15 **Sukrithan V**, Sandler J, Gucalp RA, Gralla RJ, Halmos B. Responses to immune checkpoint therapy in pulmonary sarcomatoid carcinoma: A retrospective review. *J Clin Oncol* 2019; **37**: 115-115 [DOI: 10.1200/JCO.2019.37.8_suppl.115]
 - 16 **Tiefenbacher A**, Pirker R. EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome. *J Thorac Dis* 2017; **9**: 4208-4211 [PMID: 29268473 DOI: 10.21037/jtd.2017.10.02]
 - 17 **Remon J**, Steuer CE, Ramalingam SS, Felip E. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. *Ann Oncol* 2018; **29**: i20-i27 [PMID: 29462255 DOI: 10.1093/annonc/mdx704]
 - 18 **Arcila ME**, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, Zakowski MF, Kris MG, Ladanyi M. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. *Mol Cancer Ther* 2013; **12**: 220-229 [PMID: 23371856 DOI: 10.1158/1535-7163.MCT-12-0620]



Published By Baishideng Publishing Group Inc
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-2238242
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

